Cleveland Clinic urologists are playing leading roles in the development of next-generation prostate cancer biomarkers. One new test under investigation, prostate specific antigen/solvent interaction analysis (PSA/SIA), shows promise in improving the diagnostic accuracy of screening and early detection strategies by differentiating PSA structural changes induced by cancer from those of benign glands.